| Category | Details |
| Definition | Tourette syndrome (TS) is a neurodevelopmental disorder characterized by repetitive, involuntary movements and vocalizations called tics. |
| Global Epidemiology | – TS affects 0.5–1% of the global population, with the majority diagnosed in childhood. |
| – Males are 3–4 times more likely to be affected than females. |
| – Co-occurrence with other conditions such as ADHD and OCD is common. |
| Prevalence in Key Regions | – United States: Estimated at approximately 1 million people with TS or tic disorders, with about 350,000–450,000 diagnosed with TS specifically. |
| – European Union: ~600,000 individuals affected; awareness and diagnosis rates vary. |
| – India: Largely underdiagnosed; prevalence estimated at ~1 million cases based on population studies. |
| – China: Estimated ~1.4 million individuals affected; limited access to specialized care. |
| – Caribbean: Prevalence data scarce; estimated ~50,000 individuals with TS or tic disorders. |
| Medicinal Cannabis Approvals | – United States (FDA): No specific cannabis products approved; research ongoing into cannabinoids for tics. |
| – Canada: Limited off-label use of cannabinoids for managing TS symptoms. |
| – European Union (EMA): Nabiximols studied for neurological disorders, including TS. |
| – Australia (TGA): Approved cannabinoids for refractory neurological symptoms, including tics, since 2018. |
| – Israel: Cannabis authorized for severe cases of TS since 2013. |
| Therapeutic Cannabinoids | – CBD (Cannabidiol): Reduces anxiety and agitation, potentially mitigating tic severity. |
| – THC (Tetrahydrocannabinol): Demonstrates efficacy in reducing tics and related behaviors. |
| – CBN (Cannabinol): Emerging evidence suggests sedative effects beneficial for comorbid insomnia. |
| – THCV (Tetrahydrocannabivarin): Potential for modulating neurological activity; limited clinical data. |
| Mechanism of Action | – CBD: Modulates serotonin (5-HT1A) and GABA receptors to reduce anxiety and improve mood. |
| – THC: Interacts with CB1 receptors in the brain to reduce involuntary movements and tics. |
| – CBN: Enhances relaxation through interaction with CB2 receptors; potential sedative effects. |
| Key Clinical Studies | – Müller-Vahl et al., 2003: THC significantly reduced tic severity in double-blind, placebo-controlled trial. |
| – Abi-Jaoude et al., 2020: Preliminary evidence supports cannabinoid use in reducing tics and associated behaviors. |
| – Pagano et al., 2022: Systematic review highlights the potential of cannabinoids in neurological disorders, including TS. |
| Dosage Guidelines | – THC (Oral): Start at 1–2 mg/day; titrate to ~10 mg/day based on tic severity and tolerance. |
| – CBD (Oral): Starting dose 20 mg/day; titrate to 50–100 mg/day depending on comorbid symptoms like anxiety. |
| – Nabiximols (Sativex): Up to 12 sprays/day (2.7 mg THC and 2.5 mg CBD per spray). |
| Administration Methods | – Oral Capsules: Preferred for consistent dosing in chronic management. |
| – Sublingual Oils: Rapid onset; useful for acute tic exacerbations. |
| – Inhalation: Rarely recommended due to psychoactive effects and dosing variability. |
| Adverse Effects | – THC: Psychoactive effects include dizziness, anxiety, and euphoria; potential dependency with prolonged use. |
| – CBD: Mild side effects: fatigue, diarrhea, and appetite changes; rare liver enzyme elevation. |
| – Nabiximols: Common side effects include dry mouth, dizziness, and fatigue. |
| Research Gaps | – Limited long-term studies on the efficacy and safety of cannabinoids in rare diseases like TS. |
| – Lack of standardized dosing protocols for cannabinoid therapies in TS management. |
| Opportunities in the Caribbean | – High Prevalence: Estimated ~50,000 individuals with TS or tic disorders, with limited access to advanced treatments. |
| – Cannabis Clinics: Establishing cannabinoid-focused clinics could address local needs and attract international patients. |
| – Research Hub: Leveraging regional expertise to develop cannabinoid-based therapies for rare neurological disorders. |
